Back to search
Cutaneous Angiosarcoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Cutaneous Angiosarcoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Cutaneous Angiosarcoma trials you may qualify forThis is a single arm, open-label phase II study to assess the efficacy of single agent pembrolizumab for the treatment of advanced cutaneous sarcomas. Adult pat…
Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (adv…
Cutaneous angiosarcoma is a rare cancer for which effective treatment has not been developed sufficiently. Still, because it often occurs in elderly people, the…
This phase II trial studies how well paclitaxel with and without nivolumab works in treating patients with soft tissue sarcoma that have not received taxane dru…
To find the highest tolerable dose of an mRNA vaccine that can be safely given to patients with cutaneous angiosarcoma
Angiosarcoma is a rare and aggressive form of soft tissue sarcoma. Prior work demonstrates very poor outcomes, with most patients developing metastatic disease…